- References (2)
- Inventor Info
|Antigen/Gene or Protein Targets||P450 Oxidoreductase|
|Disease Keywords||Drug metabolism|
|Relevance||A Conditional knockout mouse. Endogenous Cyp1A1 promoter driving Cre recombinase expression. Administration of 3-methylcholanthrene (3MC) results in expression of Cre recombinase and subsequent deletion of floxed P450 oxidoreductase (POR) in target organs (liver or liver and gut depending on 3MC dosage); may be used early in the drug development process to establish role of P450 activity in drug metabolism & disposition in vivo.|
|Production Details||Targeting carried out in C57BL/6 ES cells and line maintained by crossing with wild-type C57BL/6, ie CreCyp1a1-KI/+. Targeting strategy available on request.|
|Mouse Genetic Background/Cross History||C57BL/6N (There may also be a component of C57BL/6J present due to the breeding procedures undertaken by TaconicArtemis in the latter stages of generating the line)|
|Cancer, Drug Discovery & Development, Genetic Studies Tools, Metabolism|
The mouse is a.k.a. Cre Cyp1a1-Knock-In mouse.
The line is also maintained as heterozygous for the genetic alteration - it is important to note that one copy of the Cyp1a1 gene has been replaced with Cre recombinase, thus the line is also heterozygous for Cyp1a1 (although there are no apparent phenotypic consequences). However, should the line ever become homozygous for Cyp1a1-Cre, the mice would be homozygous null for Cyp1a1, and although such mice would be viable, they may have phenotypic consequences that might interfere and thus it is better to keep the line as heterozygous for Cyp1a1-Cre.
There are 2 reference entries for this reagent.View All References
Prof Roland Wolf